S104 THE BRAF INHIBITOR VEMURAFENIB COMBINED WITH RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE REMISSIONS IN RELAPSED OR REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL

Authors :: Samantha Ferrari
Enrico Tiacci
Natalia Frattarelli
L. De Carolis
Brunangelo Falini
Monia Capponi
Paolo Falcucci
R. Della Seta
Eugenio Lucia
A. Ambrosetti
Giuseppe Visani
G. Gaidano
Edoardo Simonetti
Alessandro Pulsoni
Robert Foa
Francesco Zaja
L. Rigacci
Agostino Antolino
P. L. Zinzani
Source :: HemaSphere. 3:3
Publication Year :: 2019
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2019.

Subjects :: BRAF inhibitor
business.industry
medicine
Cancer research
Refractory hairy cell leukemia
Rituximab
Hematology
Vemurafenib
business
medicine.drug

Full Text Access

Tools